PF415 EFFICACY AND SAFETY FOLLOWING DOSE REDUCTION OF BOSUTINIB IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA: ANALYSIS OF THE PHASE 4 BYOND TRIALT.H. Brümmendorf,F. Giles,C. Gambacorti‐Passerini,G.J. Roboz,P. Le Coutre,H. Hjorth‐Hansen,L. Stenke,F. Cervantes,P. Rousselot,A. Viqueira,N. Bardy‐Bouxin,E. Leip, J.M. Leone,J.L. Steegmann,J.E. Cortes,A. HochhausHemaSphere（2019）引用 0|浏览9暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
